The term ‘entourage effect’, first mentioned in 1999, describes a phenomenon where the activity of the two main active endocannabinoids (anandamide and 2-Ara-Gl) is potentiated when biologically inact . . .

Evidence suggests that the ECS contributes to the pathophysiology of schizophrenia, so a substance that modulates the ECS could be helpful in treatment.

Preclinical data suggest that CBD could be used to treat anxiety disorders.

CBD has a broad-spectrum antibacterial action, which could be helpful in the treatment of infections.